We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Test Evaluated for Human Malaria Species

By LabMedica International staff writers
Posted on 04 Jul 2012
A rapid diagnostic test (RDT) for malaria parasites has been evaluated and compared with other methods in a reference setting. More...


The three-band rapid diagnostic test detects Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH (pan-pLDH).

Scientists at Maastricht University (Netherlands) carried out a retrospective and a prospective study to assess with 498 stored and 77 fresh blood samples obtained from international travelers suspected of malaria. Both panels comprised all four Plasmodium species; the retrospective panel comprised also samples negative for malaria. The retrospective panel had been obtained between February 1996 and May 2011. The reference method was microscopy corrected by polymerase chain reaction (PCR). The prospective panel was run side-to-side with two other RDTs.

In the retrospective evaluation, overall sensitivity for the 247 P. falciparum samples was 94.7%, reaching 98.7% for parasite densities greater than 1,000/μL. Most false negative results occurred among samples with pure gametocytaemia and at parasite densities less than or equal to 100/μL. None of the 96 negative samples showed visible test lines. Sensitivities for the 70 P. vivax, 69 P. ovale and 16 P. malariae were 74.3%, 31.9% and 25.0% respectively. Overall, Pf-pLDH test lines showed higher line intensities compared to the pan-pLDH lines, with 67.9% and 23.0% medium and strong line intensities for P. falciparum.

In the prospective panel, the CareStart pLDH RDT (AccessBio Inc.; Monmouth, NJ, USA) showed higher sensitivities for P. falciparum compared to OptiMAL (Pf-pLDH/pan-pLDH, BioRad; Marnes-la-Coquette, France) and lower sensitivities for P. falciparum as compare to SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH; Standard Diagnostics; Hagal-Dong, Korea). Wrong species identification occurred in 10 (2.5%) samples and was mainly due to P. vivax samples reacting with the Pf-pLDH test line.

The authors concluded that CareStart pLDH may be an alternative to other well-described HRP-2 three band RDTs in the diagnostic setting in non-endemic areas. Despite being better than the other two RDTs that were run side by side, it should be noted that its performance for the detection of P. ovale and P. malariae is mediocre. The study was published on June 18, 2012, in the Malaria Journal.

Related Links:

Maastricht University
AccessBio Inc.
BioRad



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.